StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)

Close on Nov 17, 2026Market cap $51.50MP/E –Yield –

Gain Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Gain Therapeutics's price to sales ratio was 495.8× on Nov 30, 2023, against 194.6× a year earlier.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Nov 30, 2023495.8×+292.9
2022Dec 30, 2022202.9×−289.8
2021Dec 31, 2021492.7×–

More Gain Therapeutics figures

See a number that looks wrong?